Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2012 Oct 11;120(15):2945-53. doi: 10.1182/blood-2012-06-292078. Epub 2012 Aug 17.

Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders.

Author information

1
Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.

Abstract

The level of fetal hemoglobin (HbF) modifies the severity of the common β-globin disorders. Knowledge of the normal mechanisms that repress HbF in the adult stage has remained limited until recently despite nearly 3 decades of molecular investigation, in part because of imperfect model systems. Recent studies have provided new insights into the developmental regulation of globin genes and identified specific transcription factors and epigenetic regulators responsible for physiologic silencing of HbF. Most prominent among these regulators is BCL11A, a transcriptional repressor that inhibits adult-stage HbF expression. KLF1 and c-Myb are additional critical HbF-regulating erythroid transcription factors more broadly involved in erythroid gene expression programs. Chromatin modifiers, including histone deacetylases and DNA methyltransferases, also play key roles in orchestrating appropriate globin gene expression. Taken together, these discoveries present novel therapeutic targets for further consideration. Although substantial hurdles remain, opportunities are now rich for the rational design of HbF inducers.

PMID:
22904296
PMCID:
PMC4467860
DOI:
10.1182/blood-2012-06-292078
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center